Showing results (151-160 of 262) with videos related to
Sort By:
Pageof 27
Journal of the National Cancer Institute|December 15, 1993
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrowD P Sandler, D L Shore, J R Anderson, et al.Clinical Lymphoma|September 30, 2004
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphomaJeffrey Talbot, Valerie K Ibom, David A Rizzieri, et al.Cancer Investigation|February 15, 2013
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myelomaLauren A Held, David Rizzieri, Gwynn D Long, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Joseph O Moore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemiaSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administeredJ C Byrd, R K Dodge, A Carroll, et al.Annals of Vascular Surgery|October 15, 2019
Characterizing Reimbursements for Medicare Patients Receiving Endovascular Abdominal Aortic Aneurysm Repair at Vascular Quality Initiative CentersSpencer W Trooboff, Zachary J Wanken, Barbara Gladders, et al.Leukemia & Lymphoma|September 4, 2008
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemiaArati V Rao, Islam R Younis, Gregory J Sand, et al.Pageof 27